Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2022 Oct 21;210(1):1-13.
doi: 10.1093/cei/uxac070.

British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy

S Grigoriadou  1 , R Clubbe  2 , T Garcez  3 , A Huissoon  4 , D Grosse-Kreul  5 , S Jolles  6 , K Henderson  7 , J Edmonds  3 , D Lowe  8 , C Bethune  9
Affiliations
Practice Guideline

British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy

S Grigoriadou et al. Clin Exp Immunol. .

Abstract

Currently, there is no guideline to support the use of immunoglobulin replacement therapy (IgRT) in primary and secondary immunodeficiency disorders in UK. The UK Primary Immunodeficiency Network (UK-PIN) and the British Society of Immunology (BSI) joined forces to address this need. Given the paucity of evidence, a modified Delphi approach was used covering statements for the initiation, monitoring, discontinuation of IgRT as well as home therapy programme. A group of six consultant immunologists and three nurse specialists created the statements, reviewed responses and feedback and agreed on final recommendations. This guideline includes 22 statements for initiation, 22 statements for monitoring, 11 statement for home therapy, and 19 statements for discontinuation of IgRT. Further areas of research are proposed to improve future delivery of care.

Keywords: antibodies; human; immunodeficiency disorders; immunoglobulin.

PubMed Disclaimer

Conflict of interest statement

The authors have no financial conflicts of interest.

References

    1. NHS England, Updated Commissioning Criteria for the use of therapeutic immunoglobulin (Ig) in immunology, haematology, neurology and infectious diseases in England, November 2019. http://igd.mdsas.com/wp-content/uploads/NHSE_Commissioning_Criteria_for_... (May 2022, date last accessed)
    1. Hsu, CC, Sandford, BA. The Delphi technique: making sense of consensus. Pract Assess Res Eval 2007; 12; Article 10. doi: 10.7275/pdz9-th90. - DOI
    1. Chandesris MO, Melki I, Natividad A, et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine (Baltim) 2012, 91, e1–e19. doi: 10.1097/MD.0b013e31825f95b9. - DOI - PMC - PubMed
    1. Eijkhout HW, van Der Meer JW, Kallenberg CG, et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med 2001, 135, 165–74. doi: 10.7326/0003-4819-135-3-200108070-00008. - DOI - PubMed
    1. Favre O, Leimgruber A, Nicole A, et al. Intravenous immunoglobulin replacement prevents severe and lower respiratory tract infections, but not upper respiratory tract and non-respiratory infections in common variable immune deficiency. Allergy 2005, 60, 385–90. doi: 10.1111/j.1398-9995.2005.00756.x. - DOI - PubMed

Publication types

Substances